Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

Polymorphisms associated with renal adverse effects of antiretroviral therapy in a Southern Brazilian HIV cohort

da Rocha, Ivete M.a; Gasparotto, Aline S.b; Lazzaretti, Rosmeri K.c; Notti, Regina K.c; Sprinz, Eduardoc; Mattevi, Vanessa S.a,b

doi: 10.1097/FPC.0000000000000169
ORIGINAL ARTICLES
Buy
SDC

Objective This study evaluated the impact of seven single nucleotide polymorphisms in five candidate genes (ABCB1, ABCC2, ABCC4, SLC22A6, and SLC22A11) in relation to nephrotoxicity associated with highly active antiretroviral therapy (HAART) in HIV-infected individuals.

Methods The following single nucleotide polymorphisms were genotyped by real-time PCR: ABCB1 rs1045642, ABCC2 rs717620 and rs2273697, ABCC4 rs1751034 and rs3742106, SLC22A6 rs11568626, and SLC22A11 rs11231809 in 507 HIV-infected patients from the city of Porto Alegre, Southern Brazil, receiving HAART for, at least, 1 year.

Results From the 507 HIV-infected patients recruited, 19.1% presented a reduction in estimated glomerular filtration rate (eGFR). A total of 16 (3.2%) patients fulfilled the criteria for chronic kidney disease (defined as eGFR<60 ml/min/1.73 m2). Individuals carrying at least one T allele of ABCC2 −24 C>T (rs717620) presented lower eGFR than C/C homozygotes (104±22 vs. 108±22 ml/min/1.73 m2, independent-samples t-test, P=0.040). In multivariate analysis, the predictors associated with decreased eGFR were time of treatment, tenofovir use, atazanavir/ritonavir use, and carrying one T allele of ABCC2 −24 C>T.

Conclusion Our data support the importance of genetic factors in the etiology of nephrotoxicity in patients treated with HAART. Studies to verify treatment implications of genotyping before HAART initiation may be advisable to guide the selection of an appropriate antiretroviral therapy regimen.

aGraduate Program in Pathology

bGraduate Program in Health Sciences, Federal University of Health Sciences of Porto Alegre

cHospital de Clínicas de Porto Alegre, Federal University of Rio Grande do Sul, Porto Alegre, Brazil

Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's website (www.pharmacogeneticsandgenomics.com).

Correspondence to Vanessa S. Mattevi, PhD, Programa de Pós-Graduação em Patologia, Universidade Federal de Ciências da Saúde de Porto Alegre, Rua Sarmento Leite, 245, Sala 309, 90050-170 Porto Alegre, RS, Brazil Tel: +55 51 3303 8763; fax: +55 51 3303 8718; e-mail: vmattevi@ufcspa.edu.br

Received November 25, 2014

Accepted July 22, 2015

Copyright © 2015 Wolters Kluwer Health, Inc. All rights reserved.